CN Patent

CN107137408A — 一种cdk4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2017-09-08 · 9y expired

What this patent protects

本发明涉及一种CDK4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途。具体而言，本发明涉及的CDK4/6抑制剂为化合物A或其可药用盐，芳香化酶抑制剂选自福美坦、依西美坦、法倔唑、来曲唑、伏氯唑、阿那曲唑中一种或几种。

USPTO Abstract

本发明涉及一种CDK4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途。具体而言，本发明涉及的CDK4/6抑制剂为化合物A或其可药用盐，芳香化酶抑制剂选自福美坦、依西美坦、法倔唑、来曲唑、伏氯唑、阿那曲唑中一种或几种。

Drugs covered by this patent

Patent Metadata

Patent number
CN107137408A
Jurisdiction
CN
Classification
—
Expires
2017-09-08
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hengrui Medicine Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.